Lila Sciences
Flagship Pioneering-founded AI-for-science platform building autonomous research labs for drug discovery and materials — Lila combines scientific reasoning models with robotic-experiment automation, raised a $200M seed in March 2025 and a $350M Series A (Oct 2025 with NVIDIA-backed Nov 2025 extension) reaching unicorn status, with George Church as Chief Scientist.
The Business
Lila Sciences builds a scientific-superintelligence platform — AI systems that combine reasoning over scientific literature with autonomous robotic experiment execution to compress drug-discovery cycle times against incumbent pharma R&D approaches. The autonomous-lab substrate spans life sciences (mRNA, proteins, antibodies, cell therapies, small molecules), chemical sciences and materials sciences per the company’s launch positioning. The company was founded in 2023 inside Flagship Pioneering’s labs by Geoffrey von Maltzahn (CEO and Flagship General Partner) and George Church (Chief Scientist, Harvard Medical School professor and a foundational figure in CRISPR, synthetic biology and the human genome project). Lila has raised approximately $550M+ of external capital across a March 2025 $200M seed committed from Flagship Pioneering with broad institutional participation (General Catalyst, March Capital, ARK Venture Fund, Altitude Life Science Ventures, Blue Horizon Advisors, State of Michigan Retirement System, Modi Ventures, ADIA subsidiary) and an October 2025 $350M Series A (incl. $115M Nov 2025 extension) led by Braidwell and Collective Global at a reported unicorn valuation.
Customers and Distribution
Lila Sciences is pre-commercial and does not publicly disclose revenue figures or customer-partnership terms. Distribution sits across two prospective motions: pharma and biotech partnership and licensing arrangements as the autonomous-lab substrate demonstrates validated scientific hypotheses and candidate molecules through the 2026-2028 window; and direct internal pipeline development of drug candidates derived from the autonomous-research substrate. Named pharma partnership disclosures are limited at time of writing, consistent with the pre-commercial stage; the principal commercial-trajectory anchors are the Flagship Pioneering institutional substrate (Flagship’s portfolio companies include Moderna, Generate Biomedicines, and many other biotech successes) and the strategic-investor cohort. The scientific-progress cadence through 2026 is the principal commercial-readiness variable.
Model Strategy
Lila Sciences is a Frontier-capability-first play with a Verticals overlay under the IM Framework eight-trajectories taxonomy applied to healthcare AI: the strategic bet is that scientific-superintelligence — AI reasoning over scientific literature plus autonomous robotic experiment execution — compresses drug-discovery cycle times against incumbent pharma R&D approaches, and that depth on the autonomous-lab substrate serves life, chemical and materials sciences as the next-generation research platform. The differentiation against software-only AI-for-biology platforms (AlphaFold, ESM3, RFdiffusion and the broader protein-design and structure-prediction cohort) is the integrated autonomous-lab substrate that combines AI scientific reasoning with robotic experiment execution. Lila does not operate a foundation model as its principal commercial product; the strategic bet is on the integrated autonomous-research substrate as the durable defensibility moat. The bull case rests on the Flagship Pioneering institutional substrate plus the George Church scientific leadership plus the integrated autonomous-lab differentiation; the bear case rests on the long-cycle path from autonomous-lab demonstrations to clinical-readiness drug candidates and on the competitive cadence from Isomorphic Labs, Generate Biomedicines and Recursion.
At A Glance
The Numbers
Headcount (FTE)
Funding to date
Leadership Team
Lila Sciences is founder-led with Geoffrey von Maltzahn as CEO and George Church as Chief Scientist. The senior leadership is drawn from the Flagship Pioneering institutional substrate and the broader Boston biotech ecosystem. CFO, CRO and CTO appointments as separately named roles are not publicly disclosed at time of writing. The Flagship Pioneering institutional substrate is the principal continuity signal for the senior team; succession planning at the research-lead tier is anchored by the depth of the Boston biotech research-talent funnel that Flagship operates.
IM Framework Scoring
IM’s structured assessment of Lila Sciences’s competitive position. The summary below is the headline; expand “Show the full analyst-grade analysis” near the bottom for the per-dimension reasoning and evidence. Methodology →
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| Oct 2025 | Series A | $350M (incl. $115M Nov 2025 extension) | Unicorn (reported $1B+) | Braidwell, Collective Global |
| Mar 2025 | Seed | $200M | — | Flagship Pioneering |
Cumulative external capital approximately $550M+ across the March 2025 $200M seed and the October 2025 $350M Series A (incl. $115M Nov 2025 extension). The March 2025 seed was committed from Flagship Pioneering with additional participation from General Catalyst, March Capital, ARK Venture Fund, Altitude Life Science Ventures, Blue Horizon Advisors, State of Michigan Retirement System, Modi Ventures and a wholly-owned subsidiary of the Abu Dhabi Investment Authority per BioPharma Dive. The October 2025 Series A initially closed at $235M led by Braidwell and Collective Global and was extended by $115M in Nov 2025 with NVentures (NVIDIA), In-Q-Tel and Dauntless Ventures, bringing the Series A to $350M total per Fierce Biotech. The Series A is reported to have valued Lila at unicorn status ($1B+) per named-press coverage; precise post-money figures are not consistently disclosed.
Competitive Landscape
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| Isomorphic Labs ((Alphabet, DeepMind spinout)) |
Alphabet-owned DeepMind spinout building AI drug-discovery platforms on the AlphaFold lineage; positioned as the most-capitalised pure-play AI-for-drug-discovery rival with deep Alphabet research substrate. | Pharma partnership channel including the Eli Lilly and Novartis named-collaborations; Alphabet capital and DeepMind research substrate as the structural moat. | High — DeepMind-spinout drug-discovery platform with AlphaFold lineage and deep Alphabet capital; the principal symmetric AI-for-science rival with the deepest AI-research substrate. |
| Generate Biomedicines ((Flagship Pioneering)) |
Flagship Pioneering portfolio company applying generative-AI to protein design and drug discovery; positions on programmable biology as the AI-native primitive. | Pharma partnership channel including the Amgen and Novartis named-collaborations; Flagship Pioneering institutional capital and platform substrate as the institutional moat. | Medium-high and asymmetric — adjacent Flagship Pioneering portfolio company on generative biology and drug discovery; competitive on AI-for-biology with shared institutional substrate. |
| Recursion ((NASDAQ: RXRX)) |
Public AI-for-drug-discovery platform built around high-throughput image-based phenotypic screening and the Recursion OS; merged with Exscientia in 2024 to deepen the AI drug-discovery footprint. | Pharma partnership channel including Roche, Bayer and Sanofi named-collaborations; public-market access (NASDAQ: RXRX) as a capital channel; Recursion OS as the data-platform moat. | Medium-high — public AI-for-drug-discovery platform with high-throughput image-based phenotypic screening; flanking risk on the autonomous-research-substrate lane. |
| EvolutionaryScale | AI-for-biology foundation-model lab founded by former Meta FAIR protein-team researchers; built the ESM3 family of protein-language foundation models as a programmable biology primitive. | Open-weights ESM model distribution via Hugging Face plus direct API for enterprise pharma customers; the foundation-model research credibility from the ESM lineage is the funnel. | Medium — ESM3-family protein-design foundation-model lab; competes on the biology-foundation-model layer rather than the integrated autonomous-lab surface Lila is building. |
| Big-pharma in-house AI R&D | Large-pharma in-house AI teams at Roche, Pfizer, Novartis, GSK, AstraZeneca and the broader top-20 pharma cohort; build proprietary AI-for-discovery platforms as the make-vs-buy alternative to external partnership. | Internal R&D budgets and proprietary data assets; no external GTM channel — the substitution is a make-vs-buy decision inside each pharma customer rather than a competing third-party channel. | Medium and asymmetric — large-pharma in-house AI teams (Roche, Pfizer, Novartis, GSK, AstraZeneca) build proprietary AI-for-discovery platforms; substitution risk on the customer-side make-vs-buy economics for pharma partnerships. |
Potential Risks
Long-cycle commercial readiness — autonomous-lab to clinical candidates
The strategic bet is that AI scientific reasoning plus autonomous robotic experiment execution compress drug-discovery cycle times against incumbent pharma R&D approaches. The autonomous-lab demonstrations through 2026 are the principal scientific-progress variable; the path from autonomous-lab demonstrations to clinical-readiness drug candidates is the long-cycle commercial readiness gate. The bull case is that the Flagship Pioneering institutional substrate and the George Church scientific leadership support the long-cycle research-to-clinical trajectory; the bear case is that the path from autonomous-lab demonstrations to clinical-readiness drug candidates is structurally longer than the Series A valuation implies.
Competitive cadence — Isomorphic Labs, Generate Biomedicines, Recursion
Isomorphic Labs is the principal symmetric AI-for-drug-discovery rival with the deepest AI-research substrate (DeepMind heritage, AlphaFold lineage). Generate Biomedicines competes on generative biology with shared Flagship Pioneering institutional substrate — an unusual same-institution competitive dynamic. Recursion competes on the public-platform scaled autonomous-research substrate. EvolutionaryScale competes on the biology-foundation-model layer. The bull case is that the autonomous-lab substrate plus the scientific-leadership team differentiates Lila in the cohort; the bear case is that the AI-for-science category is increasingly crowded at the Series A scale and the differentiation between platforms compresses.
Customer-side make-vs-buy — big-pharma in-house AI R&D
Big-pharma companies (Roche, Pfizer, Novartis, GSK, AstraZeneca) increasingly build proprietary AI-for-discovery platforms in-house. Any structural shift in customer-side make-vs-buy economics is a material substitution risk for Lila’s prospective partnership-pipeline. The bull case is that the autonomous-lab substrate and the scientific-leadership team differentiate Lila against in-house pharma AI teams; the bear case is that the in-housing dynamic compresses Lila’s standalone partnership-revenue surface over the long cycle.
Capital-intensity and frontier-research run-rate
Autonomous-lab build-out is capital-intensive: the $550M cumulative capital base supports the multi-year scientific-research and robotic-experimentation build-out, but the structural variable is whether the trajectory from one funding round to the next can be sustained at sufficient valuation re-marks for a long-cycle scientific platform. The D4d sub-rubric reflects this capital position favourably; the watched event is the next priced round and the cadence of scientific-progress disclosures that anchor the valuation.
Early-stage execution and executive-bench depth
Lila Sciences is a relatively early-stage company (founded 2023) with scientific-leadership-led senior leadership and no separately disclosed CFO/CRO/CTO at time of writing. The Flagship Pioneering institutional substrate compensates for the smaller standalone executive bench; the executive-bench appointments through 2026 are a material watch-item as the company scales against Isomorphic Labs, Generate Biomedicines and Recursion at the Series A unicorn valuation.
Recent IM Coverage
- Healthcare AI — sector landing May 2026.
- Healthcare AI Category Report #IM108 May 2026.
- AI Tracker — methodology and universe May 2026.
Show recent press coverage of Lila Sciences
- Mar 2025 — Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science (Flagship Pioneering)
- Mar 2025 — Flagship startup raises $200M in pursuit of ‘scientific superintelligence’ (BioPharma Dive)
- Oct 2025 — Flagship’s Lila Sciences lands $235M to expand AI-powered autonomous research labs (Fierce Biotech)
- Mar 2025 — Scientific ‘superintelligence’ firm Lila launches with $200m (Pharmaphorum)
- 2025 — Join Our Mission — Lila Sciences (Lila)
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue: Lila Sciences is pre-commercial and does not publicly disclose revenue figures. The company’s commercial trajectory is gated by the long-cycle autonomous-lab demonstration cadence and the path to pharma partnerships and clinical-readiness drug candidates. We decline-to-publish a revenue figure and reference Flagship Pioneering’s launch announcement as the canonical commercial-trajectory anchor.
- Scientific-progress demonstrations: Lila Sciences’s company website and Pharmaphorum coverage of the launch reference the autonomous-lab substrate spanning mRNA, proteins, antibodies, cell therapies and small molecules. Precise scientific-output metrics (validated hypotheses, candidate molecules, experimental throughput) are not consistently disclosed at this stage.
- Headcount: Lila Sciences does not publicly disclose precise headcount in a primary filing. LinkedIn-visible data places the company in the low-hundreds range as of mid-2026; the Flagship Pioneering substrate supports continued hiring at scientific-research and engineering positions. We decline-to-publish a precise figure and reference the careers page as the canonical entry point.
- Funding to date: Cumulative external capital approximately $550M+ through the October 2025 $350M Series A (incl. $115M Nov 2025 extension) led by Braidwell and Collective Global. The March 2025 $200M seed was committed from Flagship Pioneering with additional participation from General Catalyst, March Capital, ARK Venture Fund, Altitude Life Science Ventures, Blue Horizon Advisors, State of Michigan Retirement System, Modi Ventures and a wholly-owned subsidiary of the Abu Dhabi Investment Authority per BioPharma Dive. The Series A is reported at unicorn valuation; precise post-money figures are not consistently disclosed.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
